0HNF Stock Chart & Stats
$1.25
$0.00(0.00%)
At close: 4:00 PM EDT
$1.25
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.25 - $1.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$293.37M
Enterprise Value$292.88
Total Cash (Recent Filing)$50.83M
Total Debt (Recent Filing)$2.30M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 05, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding252,907,470
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)8.63
Price to Sales (P/S)26.40
P/FCF Ratio-19.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside460.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$12.51M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage limits fixed financial obligations and gives Lineage greater flexibility to fund clinical development. This is valuable for a development-stage biotech whose programs may require extended investment before generating commercial revenue.
Extended Cash RunwayFunding visibility into Q3 2028 reduces near-term financing pressure and supports continued advancement of multiple clinical and preclinical programs. The runway provides time to reach development milestones and pursue partner-supported funding opportunities.
Scalable Allogeneic ManufacturingA reusable, GMP-capable manufacturing platform can lower development complexity and accelerate creation of additional cell therapy assets. Demonstrated use in a clinical program also strengthens Lineage’s technology base and partnering potential.
Bears Say
Persistent Cash Burn And LossesOngoing operating losses and negative cash generation mean Lineage cannot currently fund development from its business operations. Continued burn will consume runway and may require additional financing before candidates reach approval or commercialization.
Reliance On Contingent FundingA meaningful portion of future funding is tied to events outside Lineage’s direct control, including warrant exercises, partner decisions and development milestones. Delays or non-achievement could shorten the effective runway and increase dilution or financing risk.
Clinical And Manufacturing Execution RiskThe large scale difference creates a substantial manufacturing challenge for ILT1, compounded by lower islet-cell proliferation. Separately, OpRegen timing depends on partner surgical optimization, adding execution risk to key pipeline programs.
Lineage Therap News
0HNF FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest share price was $1.25 and its highest was $1.25 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $293.37M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 68 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of -$0.028 by -$0.002.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 252,907,470 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.03 in its last earnings report, missing expectations of -$0.028. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GB:0HNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lineage Therap Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (460.00% Upside)
$7.00 (460.00% Upside)
Blogger Sentiment
Bullish
GB:0HNF Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.98%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
0HNF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented meaningful technical and strategic progress: demonstrated scalable GMP manufacturing (AlloSCOPE), rapid internal pipeline expansion (COR1, ILT1, ReSonance), and partnership validation (Roche/Genentech, Demant). Financial reporting showed an apparent improvement to net income, extension of cash runway into Q3 2028, and an incremental $4.6M ATM raise. However, material weaknesses and near-term risks remain: Q2 revenue dropped substantially (~60.7% YoY), reported profitability was driven by noncash accounting items, cash runway still depends on contingent exercises/milestones, OpRegen advancement timing is dependent on partner-driven surgical optimization, and ILT1 faces major manufacturing scale challenges. Overall, positives around technology, partnerships and program breadth are tempered by funding, revenue dynamics and technical/partner-dependent execution risks.View all GB:0HNF earnings summaries0HNF Stock 12 Month Forecast
Average Price Target
$7.00
▲(460.00% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―